Investigational Drug Development

Looking Forward

Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.

Fujifilm currently has clinical trials in the United States for cancer. These clinical trials are underway in collaboration with various institutions throughout the country.

*Avigan Tablet (favipiravir) has not been approved by the FDA for use in the USA

Investigational drug pipeline

Infectious diseases

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
T-705	RNA polymerase inhibitor	Influenza	Japan	Approved	https://clinicaltrials.gov/ct2/results?cond=&term=T-705&cntry=&state=&city=&dist=
T-705	RNA polymerase inhibitor	Severe fever with thrombocytopenia syndrome	Japan	Phase 3
T-4288	Bacterial protein synthesis inhibitor	Otorhinolaryngologic infections	Japan	IND filing
T-4288	Bacterial protein synthesis inhibitor	Respiratory tract infections	Japan	Phase 3

Oncology

Code	Mode of Action	Monotherapy or Combination	Indication	Region	Stage	Collaboration	Clinical Trial Information
FF-10501-01	IMPDH inhibitor		Myelodysplastic syndromes	Japan U.S.A.	Phase 1 Phase 2		https://clinicaltrials.gov/ct2/results?cond=&term=FF-10501-01&cntry=&state=&city=&dist=
FF-10502-01	DNA polymerase inhibitor		Advanced solid tumors	U.S.A.	Phase 2		https://clinicaltrials.gov/ct2/results?cond=&term=FF-10502-01&cntry=&state=&city=&dist=
FF-10832	Liposomal gemcitabine (DNA replication polymerase inhibitor)	Monotherapy	Advanced solid tumors (Biliary tract cancer)	U.S.A.	Phase 1		https://clinicaltrials.gov/ct2/results?cond=&term=FF-10832&cntry=&state=&city=&dist=
FF-10832		Combination with pembrolizumab¹	Advanced solid tumors (Non-small cell lung cancer and urothelial cancer)	U.S.A.	Phase 2	^*
FF-10850	Liposomal topotecan (topoisomerase I inhibitor)		Advanced solid tumors (Ovarian cancer and Merkel cell carcinoma)	U.S.A.	Phase 1		https://clinicaltrials.gov/ct2/results?cond=&term=FF-10850&cntry=&state=&city=&dist=

¹Fujifilm Begins U.S. Clinical Phase 2a Study of FF-10832 in Combination with KEYTRUDA® (pembrolizumab, Merck & Co., Inc., Rahway, N.J., U.S.A.) for Patients with Advanced Solid Tumors | Fujifilm [United States]
*Merck & Co., Inc. is known as MSD outside the United States and Canada.

Neurology

Code	Mode of Action	Indication	Region	Stage	Clinical Trial Information
T-817MA	Neuroprotectant, microglial modulator, neuroplasticity facilitator	Alzheimer’s disease	Japan U.S.A. EU	Phase 2	https://clinicaltrials.gov/ct2/results?cond=&term=T-817MA&cntry=&state=&city=&dist=
T-817MA		Functional recovery after stroke (Promoting the effect of rehabilitation)	Japan	Phase 2

The drug candidates created or tested by direct or indirect affiliates of FUJIFILM Holdings Corporation that are referred to on this page are still at development stage and not yet approved for commercialization. A future use and commercialization will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.

Expanded access/Compassionate use

Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.

Partnership Strategy

We are seeking the following partners:

Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.